person · Reporting owner

Gangolli Julian S

Disclosed activity across 4 companies

Tapewire entity: 74543
SEC CIK: 0001532023

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Krystal Biotech, Inc.KRYS · Entity 3500	Director	September 14, 2026	September 17, 2026
Outlook Therapeutics, Inc.OTLK · Entity 608	Director	October 01, 2025	October 03, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Krystal Biotech, Inc.

Report date September 14, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13	Direct	1,187	Reported balance After 2026-09-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	471	Reported balance After 2026-09-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Outlook Therapeutics, Inc.

Report date October 01, 2025 · Filed October 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-10-01	Direct	286,734	Reported balance After 2025-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-01 · Grant · Acquired 286,734 · Balance 286,734 F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Filing footnotes · ownership attribution and instrument terms

F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GW PHARMACEUTICALS PLC

Report date May 10, 2019 · Filed May 14, 2019

Section 16 reporting ended · disclosed 2019-05-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	106,548	Ending reported balance After 2019-05-10 transaction · row 11 11 source rows · reconciled sequence Row 1 · 2019-05-10 · Exercise / conversion · Acquired 403,804 · Balance 510,352 F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. Row 2 · 2019-05-10 · Exercise / conversion · Acquired 75,369 · Balance 585,721 F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Row 3 · 2019-05-10 · Exercise / conversion · Acquired 192,755 · Balance 778,476 F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F4: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Row 4 · 2019-05-10 · Sale · Disposed 117,876 · Balance 660,600 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F6: The price reported in Column 4 is a weighted average price per ordinary share ($175.57 per ADS). These shares were sold in multiple transactions at prices ranging from $174.99 per ADS (or $14.58 per ordinary share) to $175.98 per ADS (or $14.67 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2019-05-10 · Sale · Disposed 81,156 · Balance 579,444 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F7: The price reported in Column 4 is a weighted average price per ordinary share ($176.40 per ADS). These shares were sold in multiple transactions at prices ranging from $175.99 per ADS (or $14.67 per ordinary share) to $176.87 per ADS (or $14.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2019-05-10 · Sale · Disposed 65,268 · Balance 514,176 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F8: The price reported in Column 4 is a weighted average price per ordinary share ($177.58 per ADS). These shares were sold in multiple transactions at prices ranging from $177.01 per ADS (or $14.75 per ordinary share) to $177.90 per ADS (or $14.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2019-05-10 · Sale · Disposed 208,260 · Balance 305,916 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F9: The price reported in Column 4 is a weighted average price per ordinary share ($178.60 per ADS). These shares were sold in multiple transactions at prices ranging from $178.02 per ADS (or $14.84 per ordinary share) to $179.00 per ADS (or $14.92 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 8 · 2019-05-10 · Sale · Disposed 145,164 · Balance 160,752 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F10: The price reported in Column 4 is a weighted average price per ordinary share ($179.49 per ADS). These shares were sold in multiple transactions at prices ranging from $179.07 per ADS (or $14.92 per ordinary share) to $180.01 per ADS (or $15.00 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 9 · 2019-05-10 · Sale · Disposed 12,048 · Balance 148,704 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F11: The price reported in Column 4 is a weighted average price per ordinary share ($180.36 per ADS). These shares were sold in multiple transactions at prices ranging from $180.13 per ADS (or $15.01 per ordinary share) to $180.44 per ADS (or $15.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 10 · 2019-05-10 · Sale · Disposed 31,368 · Balance 117,336 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F12: The price reported in Column 4 is a weighted average price per ordinary share ($181.46 per ADS). These shares were sold in multiple transactions at prices ranging from $181.28 per ADS (or $15.11 per ordinary share) to $181.65 per ADS (or $15.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 11 · 2019-05-10 · Sale · Disposed 10,788 · Balance 106,548 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F13: The price reported in Column 4 is price per ordinary share converted from price per ADS ($182.32 per ADS).
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-15	Direct	0	Reported balance After 2019-05-10 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-05-10 · Exercise / conversion · Disposed 27,419 · Balance 0 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-15	Direct	0	Reported balance After 2019-05-10 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-05-10 · Exercise / conversion · Disposed 365,591 · Balance 0 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-15	Direct	0	Reported balance After 2019-05-10 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-05-10 · Exercise / conversion · Disposed 10,788 · Balance 0 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.61 · Expires 2025-06-24	Direct	0	Reported balance After 2019-05-10 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2019-05-10 · Exercise / conversion · Disposed 75,369 · Balance 0 F3: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2026-02-15	Direct	0	Reported balance After 2019-05-10 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2019-05-10 · Exercise / conversion · Disposed 192,755 · Balance 0 F4: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-12-24	Direct	10,603	Reported balance After 2019-05-10 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2019-05-10 · Exercise / conversion · Disposed 6 · Balance 10,603 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. F14: These stock options will originally vest on June 24, 2019. Stock options to acquire 6 ordinary shares were accelerated.

Filing footnotes · ownership attribution and instrument terms

F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.

F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.

F3: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.

F4: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.

F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019.

F6: The price reported in Column 4 is a weighted average price per ordinary share ($175.57 per ADS). These shares were sold in multiple transactions at prices ranging from $174.99 per ADS (or $14.58 per ordinary share) to $175.98 per ADS (or $14.67 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7: The price reported in Column 4 is a weighted average price per ordinary share ($176.40 per ADS). These shares were sold in multiple transactions at prices ranging from $175.99 per ADS (or $14.67 per ordinary share) to $176.87 per ADS (or $14.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8: The price reported in Column 4 is a weighted average price per ordinary share ($177.58 per ADS). These shares were sold in multiple transactions at prices ranging from $177.01 per ADS (or $14.75 per ordinary share) to $177.90 per ADS (or $14.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9: The price reported in Column 4 is a weighted average price per ordinary share ($178.60 per ADS). These shares were sold in multiple transactions at prices ranging from $178.02 per ADS (or $14.84 per ordinary share) to $179.00 per ADS (or $14.92 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10: The price reported in Column 4 is a weighted average price per ordinary share ($179.49 per ADS). These shares were sold in multiple transactions at prices ranging from $179.07 per ADS (or $14.92 per ordinary share) to $180.01 per ADS (or $15.00 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F11: The price reported in Column 4 is a weighted average price per ordinary share ($180.36 per ADS). These shares were sold in multiple transactions at prices ranging from $180.13 per ADS (or $15.01 per ordinary share) to $180.44 per ADS (or $15.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F12: The price reported in Column 4 is a weighted average price per ordinary share ($181.46 per ADS). These shares were sold in multiple transactions at prices ranging from $181.28 per ADS (or $15.11 per ordinary share) to $181.65 per ADS (or $15.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F13: The price reported in Column 4 is price per ordinary share converted from price per ADS ($182.32 per ADS).

F14: These stock options will originally vest on June 24, 2019. Stock options to acquire 6 ordinary shares were accelerated.

Revance Therapeutics, Inc.

Report date February 04, 2025 · Filed February 06, 2025

Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2025-02-06 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-02-04 · Other · Disposed 30,106 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.

F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 14, 2026 Filed Sep 17, 2026 00:00 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantRestricted Stock Units · Derivative	471	$0.00	$0.00	Disclosure SEC source: 0001532023-26-000002 · wk-form4_1789603228.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471 Underlying: Common Stock · 471 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document
September 14, 2026 Filed Sep 17, 2026 00:00 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	1,187	$0.00 Strike: $340.03	$0.00	Disclosure SEC source: 0001532023-26-000002 · wk-form4_1789603228.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187 Underlying: Common Stock · 1,187 shares Expires 2036-09-13 F1 · derivative.exercise_date: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document
October 01, 2025 Filed Oct 3, 2025 19:45 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	286,734	$0.00 Strike: $1.04	$0.00	Disclosure SEC source: 0001649989-25-000007 · primary_doc.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,734 Underlying: Common Stock · 286,734 shares Expires 2035-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
June 30, 2025 Filed Jun 30, 2025 22:23 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $137.46	$0.00	Disclosure SEC source: 0001532023-25-000005 · wk-form4_1751322218.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period. Read SEC document
February 06, 2025 Filed Feb 6, 2025 20:06 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	Disposition to issuerCommon Stock	15,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-015688 · ownership.xml · nonDerivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. Read SEC document
February 04, 2025 Filed Feb 6, 2025 20:06 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	OtherCommon Stock	30,106	$3.65	$109,886.90	Disclosure SEC source: 0000950170-25-015688 · ownership.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document
October 01, 2024 Filed Oct 3, 2024 21:22 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	71,169	$0.00 Strike: $5.22	$0.00	Disclosure SEC source: 0001415889-24-024711 · form4-10042024_011036.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,169 Underlying: Common Stock · 71,169 shares Expires 2034-10-01 F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 01, 2024 Filed Oct 3, 2024 21:22 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	56,636	$0.00 Strike: $5.22	$0.00	Disclosure SEC source: 0001415889-24-024711 · form4-10042024_011036.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,636 Underlying: Common Stock · 56,636 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
June 30, 2024 Filed Jul 1, 2024 23:37 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $183.64	$0.00	Disclosure SEC source: 0001532023-24-000010 · wk-form4_1719877048.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period. Read SEC document
May 20, 2024 Filed May 22, 2024 22:17 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $22.75	$0.00	Disclosure SEC source: 0001532023-24-000008 · wk-form4_1716416222.xml · derivative · entry 5 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options were awarded on March 1, 2019 and vested monthly over a three-year period. Read SEC document
May 20, 2024 Filed May 22, 2024 22:17 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	SaleCommon Stock	1,980	$165.76	$328,200.05	Disclosure SEC source: 0001532023-24-000008 · wk-form4_1716416222.xml · nonDerivative · entry 4 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: The transaction was executed in multiple trades ranging from $165.160 to $166.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
May 20, 2024 Filed May 22, 2024 22:17 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	SaleCommon Stock	7,090	$164.34	$1,165,179.82	Disclosure SEC source: 0001532023-24-000008 · wk-form4_1716416222.xml · nonDerivative · entry 3 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 F2 · price: The transaction was executed in multiple trades ranging from $164.085 to $164.850. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
May 20, 2024 Filed May 22, 2024 22:17 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	SaleCommon Stock	10,930	$163.71	$1,789,309.86	Disclosure SEC source: 0001532023-24-000008 · wk-form4_1716416222.xml · nonDerivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,070 F1 · price: The transaction was executed in multiple trades ranging from $163.080 to $164.065. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
May 20, 2024 Filed May 22, 2024 22:17 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	Exercise / conversionCommon Stock	20,000	$22.75	$455,000.00	Disclosure SEC source: 0001532023-24-000008 · wk-form4_1716416222.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2024 Filed May 3, 2024 08:44 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	23,458	$0.00 Strike: $3.80	$0.00	Disclosure SEC source: 0001479290-24-000086 · wk-form4_1714740263.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2034-04-30 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 01, 2024 Filed May 3, 2024 08:44 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001479290-24-000086 · wk-form4_1714740263.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,106 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
March 07, 2024 Filed Mar 8, 2024 16:13 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	94,441	$0.00 Strike: $0.41	$0.00	Disclosure SEC source: 0001415889-24-007335 · form4-03082024_090352.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,441 Underlying: Common Stock · 94,441 shares Expires 2034-03-07 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 04, 2023 Filed Oct 6, 2023 08:16 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	370,282	$0.00 Strike: $0.24	$0.00	Disclosure SEC source: 0001209191-23-052271 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,282 Underlying: Common Stock · 370,282 shares Expires 2033-10-04 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
June 30, 2023 Filed Jul 3, 2023 20:16 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	6,800	$0.00 Strike: $117.40	$0.00	Disclosure SEC source: 0001711279-23-000049 · wk-form4_1688415354.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period. Read SEC document
May 03, 2023 Filed May 5, 2023 17:15 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	5,915	$0.00 Strike: $33.61	$0.00	Disclosure SEC source: 0001479290-23-000064 · wf-form4_168332131583022.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,915 Underlying: Common Stock · 5,915 shares Expires 2033-05-02 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Gangolli's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 03, 2023 Filed May 5, 2023 17:15 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	3,534	$0.00	$0.00	Disclosure SEC source: 0001479290-23-000064 · wf-form4_168332131583022.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,106 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Gangolli's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
March 29, 2023 Filed Mar 31, 2023 17:46 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	41,065	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0001209191-23-021907 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,065 Underlying: Common Stock · 41,065 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 05, 2022 Filed Oct 7, 2022 16:36 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	74,398	$0.00 Strike: $1.25	$0.00	Disclosure SEC source: 0001209191-22-053119 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,398 Underlying: Common Stock · 74,398 shares Expires 2032-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
June 30, 2022 Filed Jul 1, 2022 20:05 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	6,800	$0.00 Strike: $65.66	$0.00	Disclosure SEC source: 0001711279-22-000034 · wf-form4_165670592393510.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period. Read SEC document
May 04, 2022 Filed May 6, 2022 18:18 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	11,343	$0.00 Strike: $18.12	$0.00	Disclosure SEC source: 0001479290-22-000061 · wf-form4_165187552266324.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343 Underlying: Common Stock · 11,343 shares Expires 2032-05-03 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 04, 2022 Filed May 6, 2022 18:18 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	6,059	$0.00	$0.00	Disclosure SEC source: 0001479290-22-000061 · wf-form4_165187552266324.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,572 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
May 04, 2022 Filed May 13, 2022 18:14 UTC Amendment	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	10,756	$0.00 Strike: $18.12	$0.00	Disclosure SEC source: 0001479290-22-000069 · wf-form4a_165248002605949.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,756 Underlying: Common Stock · 10,756 shares Expires 2032-05-03 F1 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Gangolli's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy. Read SEC document
March 23, 2022 Filed Mar 24, 2022 17:42 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	21,878	$0.00 Strike: $1.92	$0.00	Disclosure SEC source: 0001209191-22-020955 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,878 Underlying: Common Stock · 21,878 shares Expires 2032-03-23 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document
October 05, 2021 Filed Oct 7, 2021 17:07 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	44,466	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001209191-21-059952 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,466 Underlying: Common Stock · 44,466 shares Expires 2031-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
June 30, 2021 Filed Jul 2, 2021 15:33 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	6,800	$0.00 Strike: $68.00	$0.00	Disclosure SEC source: 0001711279-21-000018 · wf-form4_162524001713056.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2031-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period. Read SEC document
May 05, 2021 Filed May 7, 2021 19:06 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	7,551	$0.00 Strike: $27.91	$0.00	Disclosure SEC source: 0001479290-21-000108 · wf-form4_162042878677999.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2031-05-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 05, 2021 Filed May 7, 2021 19:06 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	4,013	$0.00	$0.00	Disclosure SEC source: 0001479290-21-000108 · wf-form4_162042878677999.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,513 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
March 24, 2021 Filed Mar 26, 2021 18:09 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	20,873	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001209191-21-023284 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,873 Underlying: Common Stock · 20,873 shares Expires 2031-03-24 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document
October 05, 2020 Filed Oct 5, 2020 18:41 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	150,748	$0.51 Strike: $0.71	$77,499.55	Disclosure SEC source: 0001209191-20-053865 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,748 Underlying: Common Stock · 150,748 shares Expires 2030-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
July 17, 2020 Filed Jul 21, 2020 18:05 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	125,000	$0.00 Strike: $1.58	$0.00	Disclosure SEC source: 0001209191-20-043217 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:40 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	35,006	$0.99 Strike: $1.28	$34,491.41	Disclosure SEC source: 0001209191-20-041363 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,006 Underlying: Common Stock · 35,006 shares Expires 2030-07-01 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") in lieu of $34,491.76 cash fees payable under the Issuer's non-employee Director compensation program, and vest on the last day of the remaining fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document
June 30, 2020 Filed Aug 8, 2020 00:22 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	6,800	$0.00 Strike: $41.42	$0.00	Disclosure SEC source: 0000899243-20-021813 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2030-06-29 F1 · derivative.exercise_date: The options were awarded on June 30, 2020 and vest in equal monthly tranches over a one-year period. Read SEC document
May 14, 2020 Filed May 15, 2020 18:33 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	12,000	$0.00 Strike: $19.40	$0.00	Disclosure SEC source: 0001479290-20-000064 · wf-form4_158958200371566.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-05-13 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 14, 2020 Filed May 15, 2020 18:33 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0001479290-20-000064 · wf-form4_158958200371566.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
April 20, 2020 Filed Apr 21, 2020 18:39 UTC	Outlook Therapeutics, Inc. OTLK · Entity 608	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001209191-20-025303 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-04-20 F1 · derivative.exercise_date: The option will vest in three equal annual installments such that the stock option will be fully vested as of the third anniversary of the grant date, subject to (x) the Reporting Person's Continuous Service to the Issuer through such vesting date and (y) acceleration upon a Change in Control. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	6	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · derivative · entry 17 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,603 Underlying: Ordinary Shares · 6 shares Expires 2019-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. F14 · derivative.exercise_date: These stock options will originally vest on June 24, 2019. Stock options to acquire 6 ordinary shares were accelerated. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	192,755	$0.00 Strike: $3.72	$0.00	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · derivative · entry 16 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 192,755 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	75,369	$0.00 Strike: $10.61	$0.00	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · derivative · entry 15 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 75,369 shares Expires 2025-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	10,788	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · derivative · entry 14 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,788 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	365,591	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · derivative · entry 13 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 365,591 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	27,419	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · derivative · entry 12 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 27,419 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	10,788	$15.19	$163,869.72	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 11 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,548 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F13 · price: The price reported in Column 4 is price per ordinary share converted from price per ADS ($182.32 per ADS). Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	31,368	$15.12	$474,284.16	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 10 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,336 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F12 · price: The price reported in Column 4 is a weighted average price per ordinary share ($181.46 per ADS). These shares were sold in multiple transactions at prices ranging from $181.28 per ADS (or $15.11 per ordinary share) to $181.65 per ADS (or $15.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	12,048	$15.03	$181,081.44	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 9 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,704 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F11 · price: The price reported in Column 4 is a weighted average price per ordinary share ($180.36 per ADS). These shares were sold in multiple transactions at prices ranging from $180.13 per ADS (or $15.01 per ordinary share) to $180.44 per ADS (or $15.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	145,164	$14.96	$2,171,653.44	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 8 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,752 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F10 · price: The price reported in Column 4 is a weighted average price per ordinary share ($179.49 per ADS). These shares were sold in multiple transactions at prices ranging from $179.07 per ADS (or $14.92 per ordinary share) to $180.01 per ADS (or $15.00 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.